iMDx Funds $100K Grant for dd-cfDNA Testing Research
Insight Molecular Diagnostics (iMDx) and the American Society of Transplant Surgeons (ASTS) announced a $100,000 research grant. The grant, funded by iMDx and administered by ASTS, was awarded to Drs. Kenneth Andreoni and Kenneth Chavin to study the health economics of in-house versus send-out donor-derived cell-free DNA (dd-cfDNA) testing in kidney transplantation. This research aims to provide critical data to guide transplant programs and support the future commercialization of iMDx's GraftAssureDx™, which is currently under FDA review.
Key Highlights
- Insight Molecular Diagnostics (iMDx) funded a $100,000 research grant.
- Grant administered by the American Society of Transplant Surgeons (ASTS).
- Recipients: Kenneth Andreoni, MD, and Kenneth Chavin, MD, MBA, PhD, FACS.
- Research compares in-house vs. send-out dd-cfDNA testing in kidney transplantation.
- Results will support future commercialization planning for GraftAssureDx™.
- GraftAssureDx™ is currently under FDA review via the Class II de novo pathway.
Price Impact
More from IMDX
Insight Molecular Diagnostics Shareholders Approve 1.75M Share Increase for Equity Plan
Insight Molecular Diagnostics' GraftAssure Assay Shows Superiority
Insight Molecular Diagnostics to Highlight GraftAssure at Transplant Congress